Outcome of Board Meeting is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lime Chemicals' Board approved unaudited standalone results for Q3 FY26 on 14 Feb 2026, with auditors giving an unmodified (clean) limited review opinion. Revenue from operations fell sharply to Rs. 153.17 lakhs in Q3, down from Rs. 260.28 lakhs in Q3 last year — roughly a 41% drop. For the nine months ended December 2025, revenue declined to Rs. 483.88 lakhs versus Rs. 802.63 lakhs a year ago. The company slipped into a loss of Rs. 7.97 lakhs in Q3 (vs. a profit of Rs. 6.35 lakhs last year) and a cumulative nine-month loss of Rs. 20.52 lakhs (vs. a profit of Rs. 16.26 lakhs). The previous quarter (Q2 FY26) was also a loss of Rs. 15.94 lakhs, indicating a continuing trend of weakness. Notably, the company has not provisioned Rs. 36.25 lakhs of interest owed to an MSME supplier due to a quality dispute, which remains a contingent liability.
Negative for shareholders — both top line and bottom line have deteriorated sharply, with the company now reporting back-to-back quarterly losses. The unresolved MSME dispute and pending Labour Code provisions add small but real overhangs; expect continued pressure on the stock and on FY26 full-year earnings.